Traders bought shares of Gilead Sciences Inc. (NASDAQ:GILD) on weakness during trading hours on Monday. $134.02 million flowed into the stock on the tick-up and $105.27 million flowed out of the stock on the tick-down, for a money net flow of $28.75 million into the stock. Of all companies tracked, Gilead Sciences had the 9th highest net in-flow for the day. Gilead Sciences traded down ($0.08) for the day and closed at $80.92

Several equities research analysts recently issued reports on the company. Vetr raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $107.61 price target on the stock in a research report on Tuesday, April 26th. Credit Suisse Group AG reissued an “outperform” rating and set a $120.00 price target (up from $116.00) on shares of Gilead Sciences in a research report on Thursday, April 28th. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, April 29th. Morgan Stanley reissued a “hold” rating and set a $107.00 price target on shares of Gilead Sciences in a research report on Friday, April 29th. Finally, Citigroup Inc. dropped their price target on Gilead Sciences from $110.00 to $105.00 and set a “buy” rating on the stock in a research report on Friday, April 29th. Ten investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $107.37.

The stock has a 50 day moving average of $82.77 and a 200 day moving average of $87.37. The firm has a market capitalization of $106.79 billion and a PE ratio of 7.10.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.02 by $0.06. The company had revenue of $7.78 billion for the quarter, compared to the consensus estimate of $7.80 billion. The business’s revenue was down 5.7% on a year-over-year basis. During the same period in the prior year, the firm posted $3.15 earnings per share. On average, analysts predict that Gilead Sciences Inc. will post $11.78 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 29th. Stockholders of record on Friday, September 16th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.32%. The ex-dividend date is Wednesday, September 14th.

In other news, CEO John F. Milligan sold 112,000 shares of Gilead Sciences stock in a transaction on Monday, June 6th. The shares were sold at an average price of $86.94, for a total transaction of $9,737,280.00. Following the completion of the sale, the chief executive officer now directly owns 1,170,963 shares of the company’s stock, valued at approximately $101,803,523.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction on Friday, July 1st. The stock was sold at an average price of $83.12, for a total transaction of $166,240.00. Following the sale, the executive vice president now directly owns 63,122 shares of the company’s stock, valued at $5,246,700.64. The disclosure for this sale can be found here.

Several hedge funds recently bought and sold shares of the company. Morgan Stanley increased its stake in Gilead Sciences by 18.0% in the fourth quarter. Morgan Stanley now owns 10,614,126 shares of the biopharmaceutical company’s stock worth $1,074,043,000 after buying an additional 1,616,773 shares in the last quarter. Boston Partners increased its stake in Gilead Sciences by 1.4% in the fourth quarter. Boston Partners now owns 6,843,182 shares of the biopharmaceutical company’s stock valued at $692,462,000 after buying an additional 93,588 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in Gilead Sciences by 43.3% in the fourth quarter. BNP Paribas Arbitrage SA now owns 3,213,246 shares of the biopharmaceutical company’s stock valued at $325,148,000 after buying an additional 970,463 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Gilead Sciences by 8.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,913,602 shares of the biopharmaceutical company’s stock valued at $294,847,000 after buying an additional 228,120 shares in the last quarter. Finally, Mizuho Trust & Banking Co. Ltd. increased its stake in Gilead Sciences by 1.0% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 2,277,664 shares of the biopharmaceutical company’s stock valued at $232,686,000 after buying an additional 23,105 shares in the last quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.